Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2022-11-02 Interim / Quarterly Rep…
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2022
2022-11-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release with financial results for the quarter ended September 30, 2022. The document states that the financial results are provided in an attached press release (Exhibit 99.1) and that the information is being furnished, not filed, indicating this is an announcement rather than the full financial report itself. The length of the document is 3868 characters, which is relatively short and consistent with a current report or earnings release announcement. The content aligns with an Earnings Release (ER) as it announces quarterly financial results highlights. Therefore, the appropriate classification is Earnings Release (ER).
2022-11-02 English
PRIMARY DOCUMENT
Director's Dealing
2022-10-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the initiation of Phase 2 clinical trials and other related updates about the company's drug development program. It does not contain financial statements or detailed financial performance data. It is not an earnings release, annual report, or interim report. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a significant event (clinical trial initiation) and related risk factors. Therefore, it fits best under Regulatory Filings (RNS). The document length is over 10,000 characters and contains substantive information, not just a brief announcement or certification, so it is not RPA or a certification filing.
2022-10-06 English
PRIMARY DOCUMENT
Director's Dealing
2022-10-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events or other material information that shareholders should know about between periodic reports. The content describes a notice of discontinuation by a partner company regarding development of licensed products, and discusses contractual rights and potential impacts. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. It is not a call transcript, proxy, or governance document. The document is a regulatory announcement of a material event affecting the company, fitting the category of Regulatory Filings (RNS). The document length is 6940 characters, which is consistent with a detailed 8-K filing but not a full financial report. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-09-21 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.